<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1902">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03082118</url>
  </required_header>
  <id_info>
    <org_study_id>CD1007</org_study_id>
    <nct_id>NCT03082118</nct_id>
  </id_info>
  <brief_title>Vesair Continued Access Trial</brief_title>
  <acronym>VESICAL</acronym>
  <official_title>Vesair Continued Access Trial: Use of the VesairÂ® Bladder Control System in the Treatment of Post-Menopausal Female Subjects With Stress Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solace Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Solace Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single arm study of the Vesair Balloon in postmenopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All women enrolled will be treated with the vesair balloon and followed for a maximum of 3
      years, with balloon replacement annually.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All women enrolled are treated.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement on patient-reported outcomes</measure>
    <time_frame>3-12 months</time_frame>
    <description>Improvement reported on questionnaires</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in leakage events</measure>
    <time_frame>3-12 months</time_frame>
    <description>Reduction in leakage events reported on a voiding diary</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Vesair Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects treated with the Vesair Bladder Control System at enrollment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vesair Bladder Control System</intervention_name>
    <description>Intravesical balloon</description>
    <arm_group_label>Vesair Arm</arm_group_label>
    <other_name>Vesair Balloon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post-menopausal women with SUI or stress predominant mixed incontinence

          -  Maximum score on IQOL of 60

          -  Positive cough test for leakage

          -  Willing to undergo procedures

          -  Free from infection

          -  Have previously tried (and failed) noninvasive treatment for SUI

        Exclusion Criteria:

          -  SUI due to SUI

          -  Urge-predominant mixed incontinence

          -  Incontinence of neurogenic etiology

          -  2 or more UTIs in past year and 1 in past 3 months

          -  Surgery for SUI in the past 6 months

          -  taking medication that can be used to treat SUI

          -  taking medication that affects urinary symptoms for less than 3 months

          -  undergoing biofeedback

          -  Grade 3 or worse cystocele

          -  last menstrual period within 12 months

          -  oral progesterone or estrogen in the past 12 months

          -  BMI &gt; 40

          -  involuntary detrusor contractions or discomfort during bladder filling

          -  previous stage III or worse cancer

          -  previous cancer of the urinary tract

          -  previous symptoms for early stage cancer in the past 2 years

          -  anticoagulation therapy other than aspirin

          -  history of prosthetic heart valve

          -  neurological or connective tissue condition or disease affecting bladder function

          -  known allergy to device components
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joshua Freeman</last_name>
    <phone>5082831200</phone>
    <phone_ext>168</phone_ext>
    <email>jfreeman@solacetx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Shugrue</last_name>
    <phone>5082831200</phone>
    <phone_ext>165</phone_ext>
    <email>nshugrue@solacetx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute for Female Pelvic Medicine and Reconstructive Surgery</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Taff, MSN</last_name>
      <phone>610-435-9575</phone>
      <email>ETaff@fpminstitute.com</email>
    </contact>
    <contact_backup>
      <last_name>Vincent Lucente, MD</last_name>
      <phone>610-435-9575</phone>
    </contact_backup>
    <investigator>
      <last_name>Miles Murphy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonya Ephraim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 20, 2017</lastchanged_date>
  <firstreceived_date>March 11, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
